Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADEPT Study
NCT05487885Phase 4Completed
- Start
- Jul 2022
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of ketamine in major depressive disorder (MDD), anhedonia ((none)). Started Jul 2022; status: completed.
02
Drugs
ketamine
03
Conditions
major depressive disorder (MDD)anhedonia ((none))
Beyond the preview
Go deeper on NCT05487885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05487885.